| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 8410134 | Drug Discovery Today | 2017 | 8 Pages | 
Abstract
												Structure-based computational drug discovery efforts have traditionally focused on the structure of a single, well-known drug target. Important applications, such as target deconvolution and the analysis of polypharmacology, require proteome-scale molecular docking and have been inaccessible to structure-based in silico approaches. One important reason for this inaccessibility was that the structure of most proteins was not known. Lately, this 'structure gap' has been closing rapidly, and proteome-scale molecular docking seems within reach. Here, we survey the current state of structural coverage of the human genome and find that coverage is truly proteome-wide, both overall and in most pharmaceutically relevant categories of proteins. The time is right for structure-based approaches to target deconvolution and polypharmacology.
											Related Topics
												
													Life Sciences
													Biochemistry, Genetics and Molecular Biology
													Biotechnology
												
											Authors
												Joseph C. Somody, Stephen S. MacKinnon, Andreas Windemuth, 
											